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Summary
Background Evidence for the effectiveness of vitiligo treatments is limited.
Objectives To determine the effectiveness of (i) handheld narrowband UVB (NB-
UVB) and (ii) a combination of potent topical corticosteroid (TCS) and NB-UVB,
compared with TCS alone, for localized vitiligo.
Methods A pragmatic, three-arm, placebo-controlled randomized controlled trial
(9-month treatment, 12-month follow-up). Adults and children, recruited from
secondary care and the community, aged ≥ 5 years and with active vitiligo
affecting < 10% of skin, were randomized 1 : 1 : 1 to receive TCS (mometasone
furoate 01% ointment + dummy NB-UVB), NB-UVB (NB-UVB + placebo TCS)
or a combination (TCS + NB-UVB). TCS was applied once daily on alternating
weeks; NB-UVB was administered on alternate days in escalating doses, adjusted
for erythema. The primary outcome was treatment success at 9 months at a tar-
get patch assessed using the participant-reported Vitiligo Noticeability Scale, with
multiple imputation for missing data. The trial was registered with number
ISRCTN17160087 on 8 January 2015.
Results In total 517 participants were randomized to TCS (n = 173), NB-UVB
(n = 169) and combination (n = 175). Primary outcome data were available for
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370 (72%) participants. The proportions with target patch treatment success
were 17% (TCS), 22% (NB-UVB) and 27% (combination). Combination treat-
ment was superior to TCS: adjusted between-group difference 109% (95% confi-
dence interval 10%–209%; P = 0032; number needed to treat = 10). NB-UVB
alone was not superior to TCS: adjusted between-group difference 52% (95%
CI  44% to 149%; P = 029; number needed to treat = 19). Participants using
interventions with ≥ 75% expected adherence were more likely to achieve treat-
ment success, but the effects were lost once treatment stopped. Localized grade 3
or 4 erythema was reported in 62 (12%) participants (including three with
dummy light). Skin thinning was reported in 13 (25%) participants (including
one with placebo ointment).
Conclusions Combination treatment with home-based handheld NB-UVB plus TCS
is likely to be superior to TCS alone for treatment of localized vitiligo. Combina-
tion treatment was relatively safe and well tolerated but was successful in only
around one-quarter of participants.
What is already known about this topic?
• Vitiligo is a common condition, and can have a considerable psychological impact.
• Topical corticosteroids (TCSs) are standard care for vitiligo. Narrowband ultraviolet
B (NB-UVB) is a widely used treatment, but it is usually only available as full-body
treatment, delivered in secondary care.
• Evidence for the use of handheld NB-UVB in combination with TCSs is very lim-
ited.
What does this study add?
• For people with localized nonsegmental vitiligo, combination therapy with NB-
UVB and a potent TCS (mometasone furoate 01% ointment) is likely to result in
improved treatment response compared with potent TCS alone, but was successful
in only around one-quarter of participants.
• Both treatments are relatively safe and well tolerated when used over a period of
9 months.
• Treatment effects start to be lost soon after cessation of treatment, so ways of main-
taining treatment response once treatment is stopped need further investigation
Vitiligo causes loss of skin pigmentation, mainly due to
autoimmune destruction of melanocytes.1–7 It affects up to 2%
of the world’s population, and the age of onset is usually
between 10 and 30 years.8–13 Vitiligo has an impact on qual-
ity of life, especially if it occurs on visible sites, such as the
face and hands.14–16 It can lead to depression and anxiety,
low self-esteem and social isolation.16–19 Current clinical
guidelines20 recommend topical corticosteroids (TCSs), topical
tacrolimus, narrowband ultraviolet B (NB-UVB) and combina-
tion therapies for vitiligo. However, there are few well-de-
signed randomized controlled trials assessing NB-UVB
treatment for vitiligo.21
Many people with vitiligo experience frustration in access-
ing treatment.22–24 NB-UVB is usually reserved for people
with extensive vitiligo and is delivered in secondary care
using full-body units, requiring regular hospital attendance.22
Limited vitiligo can be treated with handheld NB-UVB
devices,25 but studies assessing these have been retrospective,
or too small to inform clinical practice.26,27 Using a hand-
held NB-UVB device reduces the need for hospital visits and
avoids exposure of unaffected skin to NB-UVB. Clinical stud-
ies have also suggested that treating vitiligo in its early stages
is more likely to be beneficial than treating long-standing
vitiligo.27,28
We report the results of the Home Interventions and
Light therapy for the treatment of Vitiligo Trial (Hi-Light
Vitiligo Trial), which evaluated the comparative safety and
effectiveness of a potent TCS and handheld NB-UVB for
the management of active limited vitiligo in adults and
children.
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Patients and methods
The trial protocol has been published previously.29,30 No
changes were made to the eligibility criteria or outcome mea-
sures after trial commencement. The study was approved by
the Health Research Authority East Midlands (Derby) Research
Ethics Committee (14/EM/1173) and the Medicines and
Healthcare products Regulatory Agency (EudraCT 2014-
003473-42). Participants or their parents or carers gave writ-
ten informed consent. The trial was informed by a pilot
trial,31 and was registered prior to the start of recruitment
(ISRCTN 17160087; 8 January 2015). A full trial report is
available through the NIHR Journal series.32
Study design and setting
The study was a multicentre, three-arm, parallel-group, prag-
matic, placebo-controlled randomized controlled trial, with
nested health economics and process evaluation studies (re-
ported separately).30
Trial interventions were delivered in secondary care across
16 UK hospitals. Participants were identified through sec-
ondary care dermatology clinics and general practice mailouts,
and by self-referral. Participants were enrolled for up to
21 months (9 months of treatment, 12 months of follow-up)
and attended hospital clinics on two consecutive days at base-
line for recruitment and training, and then at 3, 6 and
9 months to assess outcomes. Follow-up thereafter was by 3-
monthly questionnaires, by post or email.
Objectives
The study’s objectives were as follows. (1) To evaluate the
comparative effectiveness and safety of home-based interven-
tions for the management of active, limited vitiligo in adults
and children, comparing firstly, handheld NB-UVB vs. potent
TCS (mometasone furoate 01% ointment); and secondly, a
combination of handheld NB-UVB plus potent TCS vs. potent
TCS alone. (2) To assess whether treatment response (if any) is
maintained once the interventions are stopped. (3) To compare
the cost-effectiveness of the interventions from a UK National
Health Service (NHS) perspective. (4) To understand the barri-
ers and facilitators to adoption of these interventions within the
UK NHS. Objectives 3 and 4 are reported elsewhere.30
Participants
Participants were aged > 5 years, with nonsegmental vitiligo
limited to approximately 10% or less of body surface area,
and at least one vitiligo patch that had been active in the last
12 months (reported by the participant, or parent or carer).
Full eligibility criteria are listed in the protocol.29
Interventions
All participants received an NB-UVB light unit (active or
dummy; used on alternate days) and either a TCS
(mometasone furoate 01% ointment; Elocon; Merck Sharp
& Dohme, Kenilworth, NJ, USA) or vehicle (placebo), applied
daily on alternate weeks. Any device found to have an output
that had more than  20% of the expected mean output, or a
dummy device testing positive for any NB-UVB emission, was
returned to the manufacturer. Treatments were continued for
up to 9 months, and concomitant medications were logged.
Further details of the interventions are provided in the proto-
col and full trial report.29,32 Dummy devices were identical to
active devices but used special covers that blocked transmis-
sion of NB-UVB. Placebo ointment was identical in appearance
to active ointment.
Participants selected up to three patches of vitiligo for
assessment: one on each of three anatomical regions (head
and neck, hands and feet, and rest of body). One patch was
selected as the target for primary outcome assessment and was
reported as active (new or changed) within the last
12 months.
Outcomes
The outcomes examined were the core outcome domains for
vitiligo.33,34
Primary outcome
The primary outcome was participant-reported treatment suc-
cess at the target patch of vitiligo after 9 months of treatment.
This was measured using the Vitiligo Noticeability Scale
(VNS),35,36 with treatment success defined as ‘a lot less
noticeable’ or ‘no longer noticeable’ compared with before
treatment. Participants used digital images of the target patch
before treatment to help inform their assessment.
Secondary outcomes
Secondary outcomes were as follows. (i) Blinded assessment
of treatment success (VNS) at the target patch assessed by a
panel of three people with vitiligo, using digital images.
(ii) Participant-reported treatment success for each of the
three anatomical regions (all assessed patches) using VNS,
assessed at 9 months. (iii) Onset of treatment response at
the target patch, assessed by investigators. (iv) Percentage
repigmentation at the target patch at 9 months, using
blinded clinician assessment of digital images (0–24%, 25–
49%, 50–74%, 75–100%). Investigator assessments were
used if images at 9 months were unavailable. (v) Quality of
life at baseline, end of treatment (9 months) and end of
follow-up (21 months). Disease-specific quality-of-life (Viti-
QoL, Skindex 29) and generic quality-of-life (EuroQol 5
Dimensions 5 Levels; EQ-5D-5L) instruments were com-
pleted by adults aged > 18 years. Children aged 5–17 years
completed the Child Health Utility 9D (generic) and chil-
dren aged > 11 years also completed the EQ-5D-5L (gen-
eric). (vi) Maintenance of treatment response assessed by
participants for the target patch at 12, 15, 18 and
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21 months. (vii) Safety: adverse device effects, and adverse
reactions during the treatment phase. (viii) Time burden of
treatment: time per session for active NB-UVB treatment
and participant-reported treatment burden for active TCS
and NB-UVB treatments at 3, 6 and 9 months.
Adherence with treatments was recorded using treatment
diaries and was collated at 3-monthly clinic visits.
Randomization and blinding of allocation and outcome
assessment
Participants were randomized 1 : 1 : 1 to receive TCS plus
dummy NB-UVB (TCS group), vehicle ointment plus NB-UVB
(NB-UVB group), or TCS ointment plus NB-UVB (combina-
tion group). Allocation was minimized by recruiting centre,
body region of target patch and age, weighted towards mini-
mizing the imbalance in trial arms with probability 08. The
randomization sequence was accessed by staff at the recruiting
hospital, using a secure web server created and maintained by
the Nottingham Clinical Trials Unit (NCTU) to ensure con-
cealment. A central pharmacy (Mawdsleys, Doncaster, UK)
distributed the interventions. The pharmacy was notified of
the allocation for randomized participants via the web-based
system and trial treatments were sent directly to participants’
homes. Only the NCTU programmer, the pharmacy staff and
the NCTU Quality Assurance staff had access to treatment allo-
cations. Additional blinded outcome assessments were per-
formed by a panel of three people with vitiligo (for the
primary analysis) and a clinician for the secondary outcome of
percentage repigmentation, using digital images taken at base-
line and at 9 months.
Statistical methods
Sample size
Assuming that 15% of participants allocated to receive TCS
would achieve treatment success,37 372 participants were
required to detect a clinically significant absolute difference
between groups of 20%, with 25% two-sided alpha and 90%
power. Allowing for up to 15% noncollection of primary out-
come data at 9 months, the target sample size was 440 partic-
ipants. A planned sample-size review by the Data Monitoring
Committee after 18 months of recruitment resulted in a rec-
ommended increase in sample size to 516 participants.
Analysis
All analyses were prespecified in a statistical analysis plan,
which was finalized prior to database lock.29 Amendments to
the analysis plan compared with the protocol are summarized
in Table S1 (see Supporting Information).
The primary analysis included all participants, regardless of
adherence, and with multiple imputation of missing outcome
data. Estimates of the analyses were obtained from 30 multiply
imputed datasets by applying the combination rules developed
by Rubin.38 Prior to primary analysis, baseline characteristics
were summarized by treatment arms and the availability of
primary outcome at 9 months, in order to check the missing-
at-random assumption of multiple imputation.
For the primary outcome, the number and percentage of par-
ticipants achieving ‘treatment success’ were reported for each
treatment group at 9 months. Randomized groups were com-
pared using a mixed effects model for binary outcome adjusted
by minimization variables. The primary effectiveness parameter
for the two comparisons of NB-UVB alone and combination
treatment, each vs. TCS alone, was the difference in the propor-
tion of participants achieving treatment success at 9 months,
presented with the 95% confidence interval (CI) and P-value.
By default, risk differences are reported, because these estimates
are more clinically intuitive for binary outcomes. However,
where models estimating risk difference did not converge, odds
ratios are reported instead of risk differences.
Sensitivity analyses were conducted: (i) to adjust for any
variables with imbalance at baseline, (ii) to repeat the primary
analysis based on participants whose primary outcome was
available at 9 months and (iii) to investigate the effects of
treatment adherence. Complier-average causal effect analysis39
was conducted where taking ≥ 75% of expected treatments
was considered a complier. Planned subgroup analyses were:
(i) children vs. adults, (ii) by body region of the target viti-
ligo patch, (iii) by activity of the target patch (hypomelanotic
patch: definitely vs. maybe or no) and (iv) ≥ 4 years duration
of vitiligo vs. < 4 years. These analyses were conducted by
inclusion of appropriate interaction terms in the regression
model and were exploratory.
Secondary outcomes were analysed by a similar approach,
using appropriate regression modelling depending on the out-
come type. An additional post hoc subgroup analysis explored
the impact of skin type (types I–III vs. types IV–VI).
Patient and public involvement
People with vitiligo were involved in all aspects of the trial,
including prioritization of the research questions, study
design, oversight, and conduct and interpretation of the
results.32
Data sharing
Anonymized patient-level data are available from the corre-
sponding author upon reasonable request.
Results
Recruitment and participant characteristics
Recruitment was from 3 July 2015 to 1 September 2017, with
517 participants randomized (398 adults and 119 children).
Primary outcome data were available for 370 (72%) partici-
pants (Figure 1). Baseline characteristics were well balanced
across treatment groups (Table 1).
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Adherence
The median percentage of NB-UVB treatment days (actual/allo-
cated) was 81% for TCS, 77% for NB-UVB and 74% for the
combination, and for ointment 79% for TCS, 83% for NB-UVB
and 77% for combination. Just under half of participants used
the treatments for > 75% of the expected duration (Table S2;
see Supporting Information). Assuming 100% adherence, and a
Figure 1 CONSORT flow diagram. Reasons for noncollection of primary outcome data at 9 months were: not assessed in clinic (n = 4), withdrew
consent (n = 60), discontinued due to adverse effects (n = 3), lost to follow-up (n = 75) and other (n = 5). These reasons were similarly
distributed within each treatment arm. Of those who withdrew consent, 11 stated that this was due to lack of treatment response and 33 due to
time burden. Of those lost to follow-up, one stated that this was due to lack of treatment response and two due to time burden. TCS, topical
corticosteroid; UVB, ultraviolet B. aPatients could have more than one reason for exclusion
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Table 1 Baseline characteristics
Characteristic TCS (n = 173) NB-UVB (n = 169) Combination (n = 175)
Age at randomization (years), mean (SD) 386 (200) 369 (189) 370 (191)
Age of adults at randomization (years), mean (SD); n 467 (152); 133 447 (140); 130 448 (142); 135
Age of children at randomization (years), mean (SD); n 117 (37); 40 108 (35); 39 106 (33); 40
Sex male 75 (43) 88 (52) 105 (60)
Ethnicity
White 112 (65) 114 (67) 104 (59)
Indian 13 (8) 13 (8) 10 (6)
Pakistani 12 (7) 15 (9) 27 (15)
Bangladeshi 4 (2) 4 (2) 4 (2)
Black 5 (3) 3 (2) 7 (4)
Chinese 2 (1) 1 (1) 1 (1)
Other Asian (not Chinese) 5 (3) 6 (4) 6 (3)
Mixed race 9 (5) 6 (4) 6 (3)
Other 10 (6) 7 (4) 9 (5)
Missing 1 (1) 0 1 (1)
Source of recruitment
Primary care 35 (20) 36 (21) 47 (27)
Secondary care 74 (43) 67 (40) 72 (41)
Self-referral 64 (37) 66 (39) 56 (32)
Skin phototype
I 2 (1) 2 (1) 5 (3)
II 31 (18) 32 (19) 29 (17)
III 70 (40) 66 (39) 59 (34)
IV 29 (17) 34 (20) 33 (19)
V 35 (20) 25 (15) 44 (25)
VI 6 (3) 10 (6) 5 (3)
Medical history
Type I diabetes 5 (3) 3 (2) 4 (2)
Hyperthyroidism 4 (2) 2 (1) 6 (3)
Hypothyroidism 21 (12) 18 (11) 10 (6)
Addison disease 2 (1) 0 3 (2)
Pernicious anaemia 5 (3) 3 (2) 6 (3)
Alopecia areata 3 (2) 7 (4) 3 (2)
Duration of vitiligo (years), median (interquartile range) 7 (3–16) 5 (3–11) 7 (4–15)
Previous treatments used for vitiligo
Light therapy 28 (16) 26 (15) 37 (21)
Corticosteroid cream or ointment 80 (46) 75 (44) 80 (46)
Calcineurin inhibitor cream or ointment 51 (29) 39 (23) 56 (32)
Cosmetic camouflage 45 (26) 44 (26) 40 (23)
Other 20 (12) 15 (9) 17 (10)
Target patch location
Head and neck 53 (31) 52 (31) 56 (32)
Hands and feet 56 (32) 53 (31) 55 (31)
Rest of the body 64 (37) 64 (38) 64 (37)
Number of assessed patches
1 50 (29) 50 (30) 62 (35)
2 74 (43) 77 (46) 73 (42)
3 49 (28) 42 (25) 40 (23)
Target patch hypomelanotica
Definitely 52 (30) 46 (27) 52 (30)
Maybe or no 121 (70) 123 (73) 123 (70)
The data are presented as n (%) unless otherwise indicated. NB-UVB, narrowband ultraviolet B; TCS, topical corticosteroid. aIt is thought that
patches that are hypomelanotic, with poorly defined borders, are more likely to be active, and therefore more responsive to treatment.
Patches were assessed at the point of randomization using Wood’s lamp.
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participant with a skin type requiring dose escalation to the
maximum dose in the treatment schedule, we estimate the
maximum possible total dose of NB-UVB received over the 9-
month treatment period to be 4 mW cm2 9 822 s 9 135
treatment sessions = 4439 mJ cm2.
In addition to written and online video training,32 partici-
pants received face-to-face training (mean 70 min) prior to
using the treatments at home. For participants using active
light devices, the median time taken to administer the treat-
ment was approximately 20 min, including time for set-up,
administering the light, and documenting timings and side-ef-
fects in the treatment diary.
Difficulties in using the treatments are summarized in
Table S2 (see Supporting Information). Burden of treatment
was identified as an issue by 42 of 142 (30%) in the TCS
group, 38 of 140 (27%) in the NB-UVB group and 36 of 149
(24%) in the combination group, although interpretation is
difficult as all three groups used both treatments throughout
(either active or dummy/placebo). Overall, NB-UVB treatment
was reported to be more burdensome than treatment with
TCS. Burden of treatment and side-effects were the most com-
monly cited difficulties for both groups and were common
reasons for discontinuation of treatment, along with lack of
treatment response.
Blinding
At the 9-month visit, investigators reported possible unblind-
ing for 21%, 28% and 27% of participants in the TCS, NB-
UVB and combination groups, respectively. More participants
reported possible unblinding (39%, 55% and 44% in the TCS,
NB-UVB and combination groups, respectively), supporting
the need for confirmation of the primary outcome using
blinded outcome assessment.
Primary outcome
The proportions of participants who reported treatment suc-
cess (a lot less noticeable or no longer noticeable) at
9 months were 20 of 119 (17%) for TCS, 27 of 123
(22%) for NB-UVB and 34 of 128 (27%) for combination
treatment (Table 2). Combination treatment was superior to
TCS: adjusted between-group difference 109% (95% CI
10–209%; P = 0032; number needed to treat = 10). NB-
UVB alone was not superior to TCS: adjusted between-
group difference 52% (95% CI  44% to 149%;
P = 029; number needed to treat = 19) (Table 3). The
proportions of participants achieving treatment success at
each timepoint are shown in Figure S1 (see Supporting
Information).
All sensitivity analyses were consistent with the primary
analysis. Treatment effects were largest among participants
who adhered to the interventions ≥ 75% of the time (Fig-
ure S2; see Supporting Information).
There was no evidence that any of the treatments were
more effective than others for any of the predefined sub-
groups (Table S3; see Supporting Information). Post hoc
exploration of treatment response by skin type (types I–III
vs. types IV–VI) also found no differences between the
groups (Table S3).
Table 2 Primary outcome analysis
TCS (n = 173) NB-UVB (n = 169) Combination (n = 175)
Patient response to VNS at 3 months
More noticeable 16 (12) 26 (19) 15 (10)
As noticeable 70 (52) 57 (42) 62 (43)
Slightly less noticeable 34 (25) 34 (25) 47 (33)
A lot less noticeable 13 (10) 19 (14) 17 (12)
No longer noticeable 2 (1) 0 2 (1)
Patient response to VNS at 6 months
More noticeable 11 (10) 23 (20) 10 (8)
As noticeable 51 (44) 37 (33) 36 (29)
Slightly less noticeable 37 (32) 33 (29) 45 (36)
A lot less noticeable 14 (12) 18 (16) 28 (22)
No longer noticeable 2 (2) 2 (2) 7 (6)
Participants with primary outcome data at 9 months 119 (69) 123 (73) 128 (73)
Patient response to VNS at 9 months
More noticeable 18 (15) 27 (22) 17 (13)
As noticeable 53 (45) 33 (27) 32 (25)
Slightly less noticeable 28 (24) 36 (29) 45 (35)
A lot less noticeable 15 (13) 25 (20) 27 (21)
No longer noticeable 5 (4) 2 (2) 7 (5)
Patient-reported treatment successa using VNS at 9 months 20 (17) 27 (22) 34 (27)
All data are presented as n (%). NB-UVB, narrowband ultraviolet B; TCS, topical corticosteroid; VNS, Vitiligo Noticeability Scale. aTreatment
success was defined as an answer of either ‘a lot less noticeable’ or ‘no longer noticeable’.
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Secondary outcomes
Treatment success using digital images, assessed by people
with vitiligo who did not participate in the trial, was consis-
tent with the primary analysis but suggested greater treatment
effects than trial participants’ VNS assessments (Table 4).
Participant-reported treatment success at 9 months (all
assessed patches) was lower for patches on the hands and feet
than on other body regions. However, the relative effective-
ness of the three treatment groups remained similar in differ-
ent body regions (Figure S3 and Table S4; see Supporting
Information).
Most participants had onset of treatment response by
3 months, defined as the target patch having improved or
stayed the same (Figure S4; see Supporting Information), with
40% in TCS, 61% in NB-UVB and 60% in the combination
group showing improvement in their vitiligo (that is, more than
stopped spreading).
Treatment success, defined as ≥ 75% repigmentation, sup-
ported the finding that combination treatment was superior to
TCS alone, but NB-UVB alone was not superior to TCS: this
occurred in four patients (3%) for TCS, nine (8%) for NB-
UVB and 18 (15%) for combination. This gives an adjusted
odds ratio of 462 (95% CI 150–142) for combination com-
pared with TCS, and 222 (95% CI 066–751) for NB-UVB
compared with TCS (Table 5).
Long-term follow-up
The percentages of participants followed up at 12, 15, 18 and
21 months after randomization were 56%, 52%, 47% and
43%, respectively. VNS scores throughout the 21-month study
period are shown in Figure S1 (see Supporting Information).
During the follow-up phase, > 40% of participants reported
loss of treatment response by 21 months, across all groups
(Table S5; see Supporting Information). Both generic and viti-
ligo-specific quality-of-life scores were similar at follow-up
across the treatment groups (Table S6; see Supporting Infor-
mation).
Safety
In total 124 (25%) participants reported 206 treatment-related
adverse events: 33 events from 24 participants (14%) in the
TCS group, 69 events from 48 participants (28%) in the NB-
UVB group and 104 from 52 participants (30%) in the
Table 4 Secondary outcome: treatment success by blinded patient and public involvement (PPI) assessors (Vitiligo Noticeability Scale using digital
images at baseline and 9 months)
Treatment, % (n/N) Treatment success by blinded PPI assessors at 9 months (target patch)
Topical corticosteroid (TCS) 11% (12/112)
Narrowband ultraviolet B (NB-UVB) 20% (22/108)
Combination 28% (32/116)
Between-group comparisona
NB-UVB vs. TCS Adjusted risk difference (95% CI) 970% (123–182)
Adjusted odds ratio (95% CI) 222 (114–431)
Combination vs. TCS Adjusted risk difference (95% CI) 163% (702–256)
Adjusted odds ratio (95% CI) 352 (180–689)
CI, confidence interval. aAnalyses were adjusted by centre, body region of target patch and age of participant with vitiligo.
Table 3 Between-group comparisons (intention to treat)a
Treatment, % (n/N)
Patient-reported treatment success
using VNS at 9 months
Topical corticosteroid (TCS) 17% (20/119)
Narrowband ultraviolet B (NB-UVB) 22% (27/123)
Combination 27% (34/128)
Between-group comparisonb
NB-UVB vs. TCS Adjusted risk difference (95% CI) 520% (445 to 149)
Adjusted odds ratio (95% CI) 144 (077 to 270)
Combination vs. TCS Adjusted risk difference (95% CI) 109% (097 to 209)
Adjusted odds ratio (95% CI) 193 (102 to 368)
CI, confidence interval; VNS, Vitiligo Noticeability Scale. aBased on multiple imputation of missing data, pooled treatment success rates from
the multiple-imputed dataset were 17% for TCS, 23% for NB-UVB and 28% for combination treatment. bAnalyses were adjusted by centre,
body region of target patch and age of participant with vitiligo.
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combination group (Table 6). There were five serious adverse
events reported from five participants, but none was related to
a trial intervention.
Details of adverse events of particular interest (grade 3 or 4
erythema and skin thinning) are shown in Table 6. Grade 3 and
4 erythemas constituted the majority of adverse events in the NB-
UVB and combination groups, and these erythemas accounted for
the higher overall adverse event rates in these groups. Fewer
adverse events were reported in children than in adults.
Discussion
The HI-Light trial was a large, pragmatic trial of home inter-
ventions for people with active, limited vitiligo. Combination
treatment with handheld NB-UVB and potent TCS is likely to
be superior to potent TCS alone (number needed to
treat = 10), although the CIs around this result were quite
wide. We did not find clear evidence that handheld NB-UVB
monotherapy was better than TCS monotherapy. Results for
percentage repigmentation (the most commonly used outcome
in vitiligo trials)40 were consistent with the participant-re-
ported primary outcome using the VNS.
Both interventions were well tolerated. Erythema (grade 3
or 4) was the most frequently observed adverse event, but
these episodes were managed effectively and were limited to
the small areas being treated. Given the large total number of
NB-UVB treatments given across these groups, we feel that
this is an acceptable level of erythemas and it is not suggestive
of a significant safety risk. The incidence of clinical skin thin-
ning was very low despite the relatively long-term intermittent
use of potent TCS, including on the face.
All sensitivity analyses were supportive of the main findings
and participants who adhered to the treatment regimen (≥
75%) were more likely to achieve treatment success. There
was no difference between the rates of success in the
treatment groups that could be attributed to age, skin type or
duration of vitiligo.
The number of participants achieving a treatment success
with the trial interventions was low but consistent with find-
ings from other trials. A meta-analysis of studies assessing
phototherapy (whole body, as opposed to handheld) for viti-
ligo41 reported that around 19% of patients achieved a
‘marked response’ (> 75% repigmentation) after 6 months of
treatment with NB-UVB monotherapy. Participants in our
study achieved similar rates of treatment success, as measured
using the VNS (18% for NB-UVB, 28% for combination at
6 months). The better response rates for vitiligo on the head
and neck seen in our study are also consistent with previous
findings.41
There are no other studies that have compared a combina-
tion of NB-UVB and mometasone furoate with mometasone
furoate alone, so direct comparison with a combination of
treatments is not possible. The participants in our study used
mometasone furoate on alternate weeks for 9 months, which
differs from other published studies.37 We used this alternate-
week regimen on the basis of feasibility work that suggested
that this would be more acceptable than once-daily application
over a 9-month treatment period.
The Cochrane systematic review of interventions for viti-
ligo37 identified a study comparing the combination of NB-
UVB and clobetasol propionate (a more potent TCS) with NB-
UVB alone. That study suggested that combination treatment
might be more effective. However, the study was too small
for the results to be conclusive; the relative risk ratio for
achieving > 75% repigmentation was 138 (95% CI 071–
268).42
Previous small studies of home-based handheld photother-
apy devices for vitiligo have demonstrated their safety;23,24
our larger study confirms this. A recently published study of
patients undergoing long-term NB-UVB treatment (mean
Table 5 Secondary outcome: percentage repigmentation assessed by blinded dermatologist and investigators
TCS NB-UVB Combination
Repigmentation: treatment success at 9 months assessed by blinded dermatologist using
digital images of target patch




Repigmentation treatment success assessed by investigators (target patch) at:
3 months 3% (4/134) 4% (6/
136)
4% (6/143)








Between-group comparison Adjusted odds
ratioa
95% confidence interval
NB-UVB vs. TCS 222 066–751
Combination vs. TCS 462 150–142
All data are presented as % (n/N) unless otherwise indicated. Percentage repigmentation determined by blinded clinician using digital images
was used in the main percentage repigmentation analysis, with missing data replaced by corresponding values from investigator assessments
in clinic at 9 months. aAnalyses were adjusted by centre, body region of target patch and age of participant with vitiligo. Due to model con-
vergence only odds ratios could be obtained for between-group comparisons.
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number of treatments = 211) reported no increase in skin
cancer risk, suggesting that treatment can safely be continued
for longer periods than in our study, although most patients
in the study of Momen and Sarkany had skin types IV–VI.43
This was a large, pragmatic trial that controlled for the most
common causes of bias. The patient-reported primary out-
come ensured that treatment success reflected the views of
participants, and was supported by blinded outcome assess-
ment using digital images.
As found in other vitiligo trials,37 retention throughout the
trial was challenging, with just over 70% of participants pro-
viding primary outcome data at 9 months, and < 50% provid-
ing secondary outcome data by 21 months. As loss to follow-
up was higher than originally anticipated, the trial lacked
power to provide a high level of precision around the point
estimates.
The most significant drop in the number of participants
remaining in the trial was from baseline to the first follow-up
at 3 months. Many participants commented that the time bur-
den was the main reason for them doing so. Participants who
adhered to the treatment regimen ≥ 75% of the time were
more likely to achieve treatment success. This requires a sig-
nificant time commitment, which some participants found
challenging. In clinical practice, following such a treatment
regimen may not be feasible for some individuals.
This trial has good external validity as it was a large, prag-
matic trial with few exclusions, although participants with
widespread vitiligo were excluded. People with all skin types
and of all ethnicities were included in the trial as this reflected
the types of patients typically presenting for vitiligo treatment
within the UK health service. We did not exclude participants
with lighter skin types, as vitiligo can cause considerable dis-
tress in such people, as well as in those with darker skin
types.44
For people with vitiligo requiring second-line therapy,
combination treatment with potent TCS and NB-UVB may be
helpful. Patients should be informed that only about one-quar-
ter of those seeking treatment are likely to achieve a substan-
tial treatment response, that considerable time commitment is
required, and that response is likely to be slow.
This trial found considerable output variation between indi-
vidual NB-UVB devices,32 which demonstrates the need for
quality assurance testing prior to use. We would recommend
that any member of the public purchasing such a device seek
specialist dermatologist advice and quality assurance before
use.
Safety data provide reassurance that mometasone furoate
01% used intermittently ‘one week on, one week off’ for up
to 9 months is safe for both children and adults. This potent
TCS was helpful in stopping the spread of active disease and
was successful in one in six cases, supporting its use as first-
line therapy. Health economic analysis and a process evalua-
tion study were conducted alongside this trial and are reported
separately.32 Forty per cent of participants reported loss of
treatment response after stopping treatments, therefore
research into strategies to maintain treatment response is
needed.
In conclusion, combination therapy with NB-UVB and
potent TCS is likely to result in improved treatment response
compared with potent TCS alone, for people with localized
nonsegmental vitiligo. Both treatments are relatively safe and
well tolerated, but were only successful in around one-quarter
of participants.















Mild 30 32 58
Moderate 3 24 40
Severe 0 13 6
AEs by outcome




Ongoing 7 5 6
Unknown 3 5 3
Number of erythema
events in adults
2 (2)a 22 (20)a 37 (26)a
Grade 3 erythema 0 8 33
Grade 4 erythema 2 14 4
Number of erythema
events in children
1 (1)a 7 (6)a 8 (7)a
Grade 3 erythema 1 6 8








Ongoing 0 0 1
















Ongoing 2 0 1
Unknown 1 0 0
NB-UVB, narrowband ultraviolet B; TCS, topical corticosteroid.
aNumbers in parentheses are the total number of participants in
whom the adverse event occurred. bSkin thinning was defined as
any events classified as skin atrophy, skin striae, telangiectasia or
spider veins.
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